Wide Ranks

CADL

Candel Therapeutics, Inc.

4.95

Top Statistics
Market Cap 160 M Forward PE -5.44 Revenue Growth 0.00 %
Current Ratio 1.62 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.90 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 21 M Total Cash Per Share 0.6690 Total Debt 18 M
Total Debt To Equity Current Ratio 1.62 Book Value Per Share 0.4380
All Measures
Short Ratio 772.00 % Message Board Id finmb_37378731 Shares Short Prior Month 1 M
Return On Equity -4.81 City Needham Uuid f9d74846-1850-3a5e-9621-529c7426beb2
Previous Close 4.62 First Trade Date Epoch Utc 1 B Book Value 0.4380
Beta -0.8740 Total Debt 18 M Volume 679673
Price To Book 11.30 Fifty Two Week Low 0.7700 Total Cash Per Share 0.6690
Shares Short Previous Month Date 1 B Target Median Price 11.00 Audit Risk 3
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Target Mean Price 11.00 Net Income To Common -49988000 Short Percent Of Float 0.0806
Implied Shares Outstanding 32 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 695270 Average Volume10days 695270 Total Cash 21 M
Next Fiscal Year End 1 B Held Percent Insiders 0.3039 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 4.62 Target Low Price 11.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.66 Open 4.68 Free Cashflow -18402376
State MA Dividend Yield 0.00 % Return On Assets -0.5231
Time Zone Short Name EST Board Risk 6 Trailing Eps -1.73
Day Low 4.54 Address1 117 Kendrick Street Shares Outstanding 32 M
Compensation Risk 8 Price Hint 4 Target High Price 11.00
Website https://www.candeltx.com 52 Week Change 4.51 Average Volume 340167
Forward Eps -0.9100 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 153.30 % Is_sp_500 False Regular Market Day High 5.02
Profit Margins 0.00 % Fifty Two Week High 14.30 Day High 5.02
Shares Short 1 M Regular Market Open 4.68 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0555
Operating Cashflow -30866000 Currency USD Time Zone Full Name America/New_York
Market Cap 160 M Is_nasdaq_100 False Zip 02494
Quote Type EQUITY Industry Biotechnology Long Name Candel Therapeutics, Inc.
Overall Risk 6 Regular Market Day Low 4.54 Held Percent Institutions 0.2253
Current Price 4.95 Address2 Suite 450 Enterprise To Ebitda -3.90
Financial Currency USD Current Ratio 1.62 Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 21 M
Two Hundred Day Average 5.73 Governance Epoch Date 1 B Enterprise Value 135 M
Forward PE -5.44 Regular Market Volume 679673 Ebitda -34658000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.

It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.

It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.

Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.